MARKET

NEUP

NEUP

Neuphoria Therapeutics Inc
NASDAQ
3.720
-0.070
-1.85%
After Hours: 3.720 0 0.00% 16:17 12/26 EST
OPEN
3.800
PREV CLOSE
3.790
HIGH
3.820
LOW
3.714
VOLUME
24.29K
TURNOVER
--
52 WEEK HIGH
21.40
52 WEEK LOW
2.900
MARKET CAP
20.00M
P/E (TTM)
-0.9880
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NEUP last week (1215-1219)?
Weekly Report · 6d ago
Neuphoria Therapeutics Shareholders Align on Key Proposals
TipRanks · 12/17 21:39
Weekly Report: what happened at NEUP last week (1208-1212)?
Weekly Report · 12/15 10:15
Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees
TipRanks · 12/08 13:05
Press Release: Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees
Dow Jones · 12/08 13:00
Weekly Report: what happened at NEUP last week (1201-1205)?
Weekly Report · 12/08 10:14
Neuphoria Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/05 13:05
Neuphoria Therapeutics Price Target Cut to $7.00/Share From $21.00 by HC Wainwright & Co.
Dow Jones · 12/05 13:05
More
About NEUP
Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Webull offers Neuphoria Therapeutics Inc stock information, including NASDAQ: NEUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEUP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NEUP stock methods without spending real money on the virtual paper trading platform.